Helen

Chlormadinone acetate / Ethinylestradiol, the active ingredient in Helen, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age.

GNH USA supplies Helen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Helen, a combined oral contraceptive, is used to manage reproductive hormone pathways.

Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. Management of hormone‑related menstrual disorders: reduces symptoms such as dysmenorrhea and menorrhagia.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations. - Spotting: irregular light bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein clot formation. - Pulmonary embolism: blockage of lung arteries. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: anaphylaxis or angioedema. - Hepatotoxicity: liver enzyme elevation or jaundice.

Before prescribing Helen, clinicians should evaluate individual risk factors and contraindications.

Assess cardiovascular risk: avoid use in women with a history of thromboembolic disorders. Screen for liver disease: contraindicated in active liver disease. Consider smoking status: do not use in women over 35 who smoke. Review medication history: potential interactions with enzyme‑inducing drugs. Pregnancy and lactation: discontinue if pregnancy is confirmed; not recommended while breastfeeding. Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Helen may interact with several medicines that affect hormone metabolism or clotting pathways.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may markedly reduce contraceptive efficacy. - Protease inhibitors (certain antiretrovirals): can alter hormone levels and effectiveness. - St. John’s wort: may decrease plasma concentrations of the active hormones.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., carbamazepine): may require monitoring of contraceptive protection. - Anticoagulants: combined use may increase thrombotic risk. - Certain antibiotics (e.g., tetracycline): generally minimal effect but monitoring is advised.